MBX Biosciences surges after mid-stage trial win for hormone disorder drug

ReutersSep 22, 2025 2:15 PM

Shares of drug developer MBX Biosciences MBX.O more than double to $24.96

MBX says its once-weekly experimental drug, canvuparatide, met main goal in mid-stage trial for adults with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

In 12-week study, 63% of patients on canvuparatide kept calcium in normal range without needing active vitamin D or more than 600 mg of daily calcium supplements, compared with 31% on placebo, difference of which was statically significant

The drug was well tolerated with no serious adverse events, company says

MBX plans to start late-stage trial in 2026

Including session's move, MBX stock up 19.4% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Surges More Than 26% in a Single Day. Akamai Wins $1.8 Billion AI Deal From Anthropic

TradingKey - According to a Reuters report on May 8, AI startup Anthropic has signed a $1.8 billion contract with Akamai Technologies (AKAM). This deal represents the largest single contract since Akamai’s inception, a development that quickly ignited enthusiasm in the capital markets. By the close of U.S. trading on Friday, Akamai's share price surged 26.58% to $147.71, after reaching an intraday high of $149.76. The company's market capitalization has reached $21.475 billion, with its cumulative gains over the past 12 months expanding to 65%.

Why SanDisk Stock Could Soar to $4,000?

If SanDisk continues along its path and actually achieves the consensus estimate of $168 in earnings per share in one year, a P/E multiple of 22 — which is a rather conservative estimate of the S&P 500 average — would imply a stock price of close to $4,000.

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

TradingKey - Since its listing on April 2, the Roundhill Memory ETF (DRAM) has surged 88% in just 25 trading days, with assets under management (AUM) surpassing $5 billion. This pace of growth is second only to the 24-day record set by the iShares Bitcoin Trust (IBIT).

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

TradingKey - AI chipmaker Cerebras is reportedly planning to list on Nasdaq on May 14 under the ticker symbol “CBRS.” The IPO is expected to be the largest in the U.S. this year, placing Nvidia’s (NVDA) strongest challenger in the AI computing space officially under the capital market spotlight.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools